{"id":"https://openalex.org/W2904884958","doi":"https://doi.org/10.2174/9781681087016118090009","title":"Advancements in Anticancer Drug Delivery","display_name":"Advancements in Anticancer Drug Delivery","publication_year":2018,"publication_date":"2018-12-05","ids":{"openalex":"https://openalex.org/W2904884958","doi":"https://doi.org/10.2174/9781681087016118090009","mag":"2904884958"},"language":"en","primary_location":{"id":"doi:10.2174/9781681087016118090009","doi":"https://doi.org/10.2174/9781681087016118090009","is_oa":false,"landing_page_url":"https://doi.org/10.2174/9781681087016118090009","pdf_url":null,"source":{"id":"https://openalex.org/S4210199062","display_name":"Frontiers in anti-cancer drug discovery","issn_l":"1879-6656","issn":["1879-6656","2451-8395"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"book series"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Anti-Cancer Drug Discovery","raw_type":"book-chapter"},"volume":null,"type":"book-chapter","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102018491","display_name":"Vikash Kumar Yadav","orcid":"https://orcid.org/0000-0002-9581-5127","observed_orcids":["https://orcid.org/0000-0002-9581-5127"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hemant K.S. Yadav","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049005405","display_name":"Abrar E. Srouji","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Abrar E. Srouji","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063892698","display_name":"Alyazya Mohammed","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alyazya Mohammed","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5025965462","display_name":"Manar Dibi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Manar Dibi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.7761,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.6985339,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":null,"issue":null,"first_page":"287","last_page":"314"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.7616999745368958,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.7616999745368958,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.0860000029206276,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.030799999833106995,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anticancer-drug-delivery","display_name":"anticancer drug delivery","score":0.8980000019073486},{"id":"https://openalex.org/keywords/targeted-cancer-therapy","display_name":"targeted cancer therapy","score":0.8989999890327454},{"id":"https://openalex.org/keywords/avelumab","display_name":"avelumab","score":0.8309999704360962},{"id":"https://openalex.org/keywords/neratinib","display_name":"neratinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/niraparib","display_name":"niraparib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":1.0},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9760000109672546},{"id":"https://openalex.org/keywords/nonsteroidal-anti-inflammatory-drugs","display_name":"nonsteroidal anti-inflammatory drugs","score":0.8650000095367432},{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.9990000128746033},{"id":"https://openalex.org/keywords/antidiabetic-drugs","display_name":"antidiabetic drugs","score":0.8389999866485596},{"id":"https://openalex.org/keywords/combination-cancer-therapy","display_name":"combination cancer therapy","score":0.6520000100135803},{"id":"https://openalex.org/keywords/skin-cancer","display_name":"skin cancer","score":0.7879999876022339},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":1.0},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.996999979019165},{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.9929999709129333}],"concepts":[{"id":"https://openalex.org/C3018146709","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Anticancer drug","level":3,"score":0.7287859916687012},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6336338520050049},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5312625765800476},{"id":"https://openalex.org/C2779820397","wikidata":"https://www.wikidata.org/wiki/Q1392806","display_name":"Drug delivery","level":2,"score":0.4847547709941864},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42853233218193054},{"id":"https://openalex.org/C171250308","wikidata":"https://www.wikidata.org/wiki/Q11468","display_name":"Nanotechnology","level":1,"score":0.16411522030830383},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.07999435067176819}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2174/9781681087016118090009","doi":"https://doi.org/10.2174/9781681087016118090009","is_oa":false,"landing_page_url":"https://doi.org/10.2174/9781681087016118090009","pdf_url":null,"source":{"id":"https://openalex.org/S4210199062","display_name":"Frontiers in anti-cancer drug discovery","issn_l":"1879-6656","issn":["1879-6656","2451-8395"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"book series"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Anti-Cancer Drug Discovery","raw_type":"book-chapter"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W6930605291","https://openalex.org/W7160519811","https://openalex.org/W7171765007","https://openalex.org/W7204587677","https://openalex.org/W7214325958","https://openalex.org/W7143341179","https://openalex.org/W4400097665","https://openalex.org/W4415773914","https://openalex.org/W4409866862","https://openalex.org/W4410488164"],"abstract_inverted_index":{"Cancer":[0],"is":[1],"considered":[2],"one":[3],"of":[4,8,28,34,91,94,120,141],"the":[5,12,31,43,69,104,118],"leading":[6],"causes":[7],"death":[9],"worldwide.":[10],"Over":[11],"past":[13],"few":[14],"decades,":[15],"researchers":[16],"have":[17,25,68,145],"worked":[18],"reluctantly":[19],"to":[20,38,49,71],"discover":[21],"anti-cancer":[22,129],"agents":[23,53,125,144],"that":[24,152],"saved":[26],"millions":[27],"lives.":[29],"However,":[30],"devastating":[32],"statistics":[33],"increasing":[35],"mortality":[36],"due":[37],"cancer":[39,74,95,112],"every":[40],"year":[41],"explain":[42],"continuous":[44],"research":[45],"in":[46,89,111,157],"this":[47,158],"field,":[48],"figure":[50],"out":[51],"newer":[52],"and":[54,83,117,135],"approaches":[55],"for":[56],"fighting":[57],"cancer.":[58],"This":[59],"chapter":[60,105,159],"will":[61,106,153],"discuss":[62,107],"some":[63,121,138],"new":[64,139],"drugs":[65],"discovered":[66],"which":[67],"ability":[70],"effectively":[72],"target":[73],"cells":[75],"including,":[76],"avelumab,":[77],"neratinib,":[78],"niraparib,":[79],"durvalumab,":[80],"nivolumab,":[81],"Erleada":[82],"others":[84],"along":[85],"with":[86,126,149],"their":[87],"applications":[88],"treatment":[90],"various":[92],"types":[93],"like,":[96],"skin,":[97],"breast,":[98],"ovarian,":[99],"prostate,":[100],"urothelial":[101],"etc.":[102],"Additionally,":[103],"newly":[108],"adopted":[109],"strategies":[110],"therapy":[113],"through":[114],"antibody-drug":[115],"conjugates":[116],"utilization":[119],"already":[122],"established":[123],"non-cancer":[124],"a":[127],"potential":[128],"effect,":[130],"such":[131],"as":[132,160],"NSAIDs,":[133],"statins":[134],"antidiabetics.":[136],"Moreover,":[137],"combinations":[140],"known":[142],"anticancer":[143],"shown":[146],"additional":[147],"benefits":[148],"significant":[150],"results":[151],"be":[154],"further":[155],"discussed":[156],"well.":[161]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-12-22T00:00:00"}